These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 4897544)
21. Immunoadjuvant effects of bacterial genomic DNA and CpG oligodeoxynucleotides on avian influenza virus subtype H5N1 inactivated oil emulsion vaccine in chicken. Wang Y; Shan C; Ming S; Liu Y; Du Y; Jiang G Res Vet Sci; 2009 Jun; 86(3):399-405. PubMed ID: 18977008 [TBL] [Abstract][Full Text] [Related]
22. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. El Sahly H Expert Rev Vaccines; 2010 Oct; 9(10):1135-41. PubMed ID: 20923265 [TBL] [Abstract][Full Text] [Related]
23. A comparison of monovalent Hong Kong influenza virus vaccine with vaccines containing only pre-1968 Asian strains in adult volunteers. A report to the Medical Research Council Committee on Influenza and other Respiratory Virus Vaccines. Hobson D; Baker FA; Chivers CP; Reed SE; Sharp D J Hyg (Lond); 1970 Sep; 68(3):369-78. PubMed ID: 4917915 [TBL] [Abstract][Full Text] [Related]
24. Studies of inactivated influenza virus vaccines in hospital employees: reactogenicity and absenteeism. Mostow SR; Eickhoff TC; Chelgren GA; Retailliau HF; Castle M J Infect Dis; 1977 Dec; 136 Suppl():S533-8. PubMed ID: 342626 [TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults. Song JY; Cheong HJ; Hyun HJ; Seo YB; Lee J; Wie SH; Choi MJ; Choi WS; Noh JY; Yun JW; Yun JG; Kim WJ Vaccine; 2017 Jan; 35(2):313-320. PubMed ID: 27919632 [TBL] [Abstract][Full Text] [Related]
26. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Martin JT Biologicals; 1997 Jun; 25(2):209-13. PubMed ID: 9236054 [TBL] [Abstract][Full Text] [Related]
27. A novel emulsion adjuvant increases the immunogenic responses and protective efficacy of an inactivated influenza vaccine in BALB/c mice. Wang S; Ke CW; Zou LR; Jing Z; Xie GX; Li X Intervirology; 2009; 52(5):252-7. PubMed ID: 19622895 [TBL] [Abstract][Full Text] [Related]
28. [Studies on the influenza adjuvant vaccines. On the antigenicity in man of viruses emulsified in a mineral oil Drakeol 6]. Rokutanda T; Yamawaki S; Higashi T; Kato Y; Takada M Kumamoto Igakkai Zasshi; 1970 Jan; 44(1):35-65. PubMed ID: 5467151 [No Abstract] [Full Text] [Related]
29. Preparation of inactivated oil-emulsion vaccines with avian viral or Mycoplasma antigens. Stone HD; Brugh M; Hopkins SR; Yoder HW; Beard CW Avian Dis; 1978; 22(4):666-74. PubMed ID: 219830 [TBL] [Abstract][Full Text] [Related]
30. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hamouda T; Chepurnov A; Mank N; Knowlton J; Chepurnova T; Myc A; Sutcliffe J; Baker JR Hum Vaccin; 2010 Jul; 6(7):585-94. PubMed ID: 20421727 [TBL] [Abstract][Full Text] [Related]
31. Response to influenza vaccine in adjuvant 65-4. Smith JW; Fletcher WB; Peters M; Westwood M; Perkins FJ J Hyg (Lond); 1975 Apr; 74(2):251-9. PubMed ID: 1054729 [TBL] [Abstract][Full Text] [Related]
32. ANTIBODY responses and clinical reactions with saline and oil adjuvant influenza virus vaccines. The Medical Research Council's Committee Br Med J; 1955 Nov; 2(4950):1229-32. PubMed ID: 13269837 [No Abstract] [Full Text] [Related]
33. Efficacy of experimental animal and vegetable oil-emulsion vaccines for Newcastle disease and avian influenza. Stone HD Avian Dis; 1993; 37(2):399-405. PubMed ID: 8363505 [TBL] [Abstract][Full Text] [Related]
34. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828 [TBL] [Abstract][Full Text] [Related]
35. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients. Kumar D; Campbell P; Hoschler K; Hidalgo L; Al-Dabbagh M; Wilson L; Humar A Transplantation; 2016 Mar; 100(3):662-9. PubMed ID: 26335915 [TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR; JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578 [TBL] [Abstract][Full Text] [Related]
37. A TRIAL OF OIL-ADJUVANT INFLUENZA VACCINE IN A NON-EPIDEMIC SEASON. HOWELL RW; STOTT AN Br J Ind Med; 1964 Oct; 21(4):259-64. PubMed ID: 14249893 [TBL] [Abstract][Full Text] [Related]
38. Relative antigenic potency in man of polyvalent influenza virus vaccines containing isolated hemagglutinins or intact viruses. Hennessy AV; Davenport FM J Immunol; 1966 Aug; 97(2):235-8. PubMed ID: 5921312 [No Abstract] [Full Text] [Related]
39. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Rümke HC; Bayas JM; de Juanes JR; Caso C; Richardus JH; Campins M; Rombo L; Duval X; Romanenko V; Schwarz TF; Fassakhov R; Abad-Santos F; von Sonnenburg F; Dramé M; Sänger R; Ballou WR Vaccine; 2008 May; 26(19):2378-88. PubMed ID: 18407382 [TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Beyer WE; Nauta JJ; Palache AM; Giezeman KM; Osterhaus AD Vaccine; 2011 Aug; 29(34):5785-92. PubMed ID: 21624411 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]